肿瘤防治研究
腫瘤防治研究
종류방치연구
CANCER RESEARCH ON PREVENTION AND TREATMENT
2001年
1期
42-43
,共2页
梁业民%程玉峰%刘秋良%张伟%靳传红
樑業民%程玉峰%劉鞦良%張偉%靳傳紅
량업민%정옥봉%류추량%장위%근전홍
食管肿瘤%放射疗法%sIL-2R
食管腫瘤%放射療法%sIL-2R
식관종류%방사요법%sIL-2R
目的 探讨食管癌患者放疗前后血清sIL-2R的变化及临床意义。方法 用双抗体夹心ELISA法检测了50例食管癌患者放疗前后血清sIL-2R水平。结果 食管癌患者放疗前血清sIL-2R水平显著高于正常人(P＜0.001)，且随病情进展而升高。放疗后血清sIL-2R水平较放疗前显著降低(P＜0.01)。存活二年的患者放疗结束时，血清sIL-2R＜800u/ml与800u/ml两组有明显差异(P＜0.01)。结论 食管癌患者血清sIL-2R明显增高，并与肿瘤进展，预后密切相关，可为肿瘤治疗疗效和判断预后的一个重要指标。
目的 探討食管癌患者放療前後血清sIL-2R的變化及臨床意義。方法 用雙抗體夾心ELISA法檢測瞭50例食管癌患者放療前後血清sIL-2R水平。結果 食管癌患者放療前血清sIL-2R水平顯著高于正常人(P＜0.001)，且隨病情進展而升高。放療後血清sIL-2R水平較放療前顯著降低(P＜0.01)。存活二年的患者放療結束時，血清sIL-2R＜800u/ml與800u/ml兩組有明顯差異(P＜0.01)。結論 食管癌患者血清sIL-2R明顯增高，併與腫瘤進展，預後密切相關，可為腫瘤治療療效和判斷預後的一箇重要指標。
목적 탐토식관암환자방료전후혈청sIL-2R적변화급림상의의。방법 용쌍항체협심ELISA법검측료50례식관암환자방료전후혈청sIL-2R수평。결과 식관암환자방료전혈청sIL-2R수평현저고우정상인(P＜0.001)，차수병정진전이승고。방료후혈청sIL-2R수평교방료전현저강저(P＜0.01)。존활이년적환자방료결속시，혈청sIL-2R＜800u/ml여800u/ml량조유명현차이(P＜0.01)。결론 식관암환자혈청sIL-2R명현증고，병여종류진전，예후밀절상관，가위종류치료료효화판단예후적일개중요지표。
Objective To study the clinical significance of the serum sIL-2Rlevel befor and after radiotherapy in the esophageal carcinoma.Methods In this study we used the methods of ELISA to test the serum sIL-2R levels of 80 cases which including 50 cases of esophageal carcinoma and 20 cases of healthy controls.Results The serum sIL-2R level in esophageal carcinoma patients was significantly higher than that of healthy controls (P＜0.001).The serum levels of sIL-2R were significantly reduced at the end of radiotherapy(P＜0.01).The 2-year survival rate was higher among those cases with＜800u/ml sIL-2R level than those with＞800u/ml.Conclusion The serum sIL-2 level may indicate clinical meaning in judging the therapeutic effect and prognosis.
